Shine-On BioMedical Co Ltd

Shine-On BioMedical has a strong liquidity position, with a current ratio of 21.48, indicating that its current assets significantly exceed its current liabilities. However, the company has negative operating and free cash flows, at -114.75 million TWD and -109.26 million TWD, respectively, suggesting ongoing cash burn. The company is not leveraged, with a debt-to-equity ratio of 0.0, and long-term debt of only 1.36 million TWD. Profitability metrics are negative, with a return on equity of -12.16% and a return on assets of -11.6%, indicating that the company is not generating returns for shareholders or asset holders. These figures are below the typical thresholds for biotechnology firms, which often trade at higher valuations due to growth potential rather than current profitability. The company operates in a single business segment focused on anti-cancer drug development and does not disclose geographic revenue breakdowns. Given its location in Taiwan and the nature of its operations, it is likely that the majority of its revenue and operations are concentrated in the Asia-Pacific region. Shine-On BioMedical reported revenue of 30 million TWD in the latest period, but this is accompanied by an operating loss of 125.5 million TWD and a net loss of 110.3 million TWD. The company is in a high-growth phase, with significant R&D and capital expenditures, but it has not yet achieved profitability. The outlook for the next fiscal year remains uncertain, with no clear indication of when the company may transition to positive cash flow. The company faces medium liquidity risk due to its negative operating and free cash flows, despite having a strong current ratio. The risk assessment also flags that net cash is negative after subtracting total debt, which could limit the company’s ability to fund operations without external financing. The dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares. There are no recent filings or transcripts provided in the input data to indicate significant events or changes in the company’s strategic direction. However, the ongoing development of its pipeline products, including SOA101, SOA201, and SOB101, suggests that the company is investing heavily in R&D to bring new therapies to market.